Drug Discovery Informatics Market to Reach USD 15.1 Billion by 2036, Driven by Pharmaceutical R&D Investment, AI-powered Drug Discovery, and Advanced Data Analytics at 10.8% CAGR

The global drug discovery informatics market was valued at US$ 4.8 Bn in 2025 and is estimated to advance at a CAGR of 10.8% from 2026 to 2036, reaching US$ 15.1 Bn by the end of 2036. Market growth is being driven by increasing research and development expenditure in the pharmaceutical sector and rapid advancements in artificial intelligence, machine learning, predictive analytics, and computational drug discovery.

Drug discovery informatics enables researchers to manage and analyze extensive biological, chemical, genomic, toxicological, and clinical datasets. The integration of advanced computational tools is helping pharmaceutical and biotechnology companies improve target identification, compound screening, molecular modeling, drug-response prediction, and other stages of the drug development process.

The increasing complexity and cost of conventional drug discovery is also encouraging companies to adopt data-driven technologies. AI-powered platforms and integrated informatics systems can support researchers in prioritizing promising candidates, reducing repetitive experimental work, and improving decision-making across early-stage discovery workflows.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33713

Analyst Viewpoint

Surge in R&D investment in the pharmaceutical sector is a key factor fostering drug discovery informatics market development. Data-driven software and computational techniques assist researchers in optimizing drug design and development, supporting preclinical research, drug target identification, and prediction of drug resistance and potential side effects.

Advancements in data science, including sophisticated data analytics and machine learning tools, are further supporting the expansion of the drug discovery informatics industry. These technologies enable researchers to process increasingly large and complex scientific datasets and identify relationships that may not be readily apparent through conventional approaches.

Pharmaceutical and biotechnology companies are also investing significantly in AI-driven drug discovery technologies as part of broader digital transformation initiatives. The integration of informatics platforms with artificial intelligence is creating opportunities to improve R&D productivity and support more efficient development of potential therapeutic candidates.

Drug Discovery Informatics Market Overview

Drug discovery informatics involves the application of information technology and computational methods to assist researchers in the discovery and development of pharmaceutical compounds. The field incorporates artificial intelligence, advanced software, databases, data analytics, and other computational technologies to analyze large volumes of biochemical and scientific information.

Drug discovery is a complex and resource-intensive process that involves identifying and developing compounds capable of treating specific diseases or infections. Potential drug candidates must subsequently undergo extensive testing and meet stringent health and safety requirements before they can be approved for administration.

The increasing availability of biological, chemical, genomic, and toxicological data is creating a growing requirement for sophisticated informatics platforms. Bioinformatics tools and databases are continuously updated to support the organization, interpretation, and analysis of scientific information throughout drug discovery workflows.

The convergence of scientific data and computational technologies is enabling researchers to identify potential therapeutic targets, analyze molecular structures, perform virtual screening, and evaluate candidate compounds. This evolution is making informatics an increasingly important component of modern drug discovery.

Surge in Pharmaceutical R&D Investment Augmenting Market Growth

Pharmaceutical companies increasingly rely on data-driven informatics software to support preclinical research, lead identification, compound screening, and analysis of treatment efficacy. These platforms enable researchers to identify patterns, test hypotheses, and evaluate large datasets while improving the efficiency of research workflows.

Global pharmaceutical companies are substantially increasing investments in R&D as drug discovery becomes more complex and data intensive. According to Evaluate Pharma, worldwide pharmaceutical R&D spending reached approximately US$ 306 Bn in 2024, compared with around US$ 258 Bn in 2022. Global pharmaceutical R&D expenditure is projected to increase further to approximately US$ 366 Bn by 2030.

Increasing R&D expenditure is encouraging pharmaceutical and biotechnology companies to strengthen their digital research infrastructure and integrate genomic, chemical, clinical, and real-world datasets. Drug discovery informatics platforms allow researchers to centralize and standardize large volumes of scientific data while supporting compound screening, target identification, and predictive modeling.

Well-structured and interoperable datasets are also becoming increasingly important for effective deployment of artificial intelligence and machine learning across drug discovery workflows. As pharmaceutical organizations accumulate larger volumes of scientific information, informatics platforms can provide the infrastructure required to organize and utilize these datasets.

The growing application of AI further strengthens demand for advanced informatics capabilities. According to the Information Technology and Innovation Foundation, AI has the potential to improve productivity across the drug development pipeline, with early evidence indicating that it could reduce drug-development timelines by approximately 50%.

The economic incentive to improve discovery productivity is substantial. Development of a new drug can require more than US$ 2.8 Bn in R&D expenditure, highlighting the potential value of technologies that improve candidate selection and reduce inefficient research activities.

AI-enabled informatics platforms can support target identification, candidate prioritization, clinical-trial design, and reduction of repetitive experimental tasks. Consequently, continued pharmaceutical R&D investment combined with growing adoption of AI, machine learning, predictive analytics, and integrated scientific data platforms is expected to drive demand for drug discovery informatics solutions.

Advancements in Data Science Fueling Market Progress

Rapid advances in data science, artificial intelligence, machine learning, and predictive analytics are transforming pharmaceutical drug discovery. These technologies enable researchers to analyze large and complex biological and chemical datasets, identify relationships, prioritize therapeutic targets, predict molecular properties, and screen potential drug candidates more efficiently.

The Stanford University 2026 AI Index Report highlights the accelerating use of AI across biological sciences. AI-related publications in the natural sciences reached approximately 80,150 in 2025, representing a 26% increase from 2024.

The report also identified virtual cell models as an important emerging area in 2025. New models are being developed to predict cellular responses to drugs and genetic perturbations without initially requiring wet-lab experiments. The development of biological AI is increasingly dependent on the availability and quality of scientific data, reinforcing the importance of integrated, standardized, and well-managed datasets.

Growing volumes of genomic, proteomic, phenotypic, chemical, and clinical information are consequently increasing demand for advanced drug discovery informatics platforms. AI and machine learning can combine these datasets to support target identification and validation, molecular simulation, structure prediction, virtual screening, drug-response prediction, toxicity assessment, and biomarker discovery.

Advances in protein and genomic modeling are also improving the ability of researchers to understand disease mechanisms and interactions involving proteins, nucleic acids, and small molecules. The commercial relevance of these technologies is becoming increasingly evident as AI-generated drug discovery programs progress toward clinical development.

In 2025, an AI-discovered drug and target combination reached a randomized Phase 2a clinical trial for idiopathic pulmonary fibrosis, representing an important milestone in the clinical application of AI-enabled drug discovery.

Conventional drug development programs can take more than 12 years, cost approximately US$ 2.5 Bn, and experience failure rates exceeding 90%. These challenges create strong incentives for pharmaceutical and biotechnology companies to adopt informatics and machine learning technologies that can improve candidate selection and potentially reduce costly development failures.

Increasing availability of biomedical data, improvements in AI models, and the shift toward computational and data-driven discovery are therefore expected to accelerate adoption of drug discovery informatics solutions.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33713

Drug Discovery Informatics Market Regional Outlook

North America accounted for the largest share of the global drug discovery informatics market in 2025. The region benefits from a well-developed healthcare and pharmaceutical sector, significant R&D activity, advanced research infrastructure, and growing adoption of computational drug discovery technologies.

The U.S. pharmaceutical ecosystem represents a major source of demand for informatics solutions. According to the American Society of Health-System Pharmacists and the American Journal of Health-System Pharmacy, total U.S. prescription drug expenditures reached approximately US$ 915.2 Bn in 2025, representing a 12.7% increase from 2024. Overall expenditure is projected to increase another 10%–12% in 2026 and exceed US$ 1.0 Trn for the first time.

Increasing pharmaceutical expenditure, substantial R&D activity, and adoption of computational technologies are supporting continued investment in drug discovery and informatics infrastructure across the region.

Asia Pacific is emerging as the fastest-growing regional market. Expansion of pharmaceutical and biotechnology R&D, increasing drug-development outsourcing, growth of contract research organizations, and rising adoption of artificial intelligence, cloud computing, bioinformatics, and computational drug-design platforms are supporting regional growth.

China, India, Japan, South Korea, and other regional markets are strengthening domestic drug discovery capabilities and investing in data-driven research infrastructure. Current market estimates indicate that the Asia Pacific drug discovery informatics market is expected to expand at approximately 14.0% CAGR through 2036, faster than other major regions.

India represents an important component of the regional pharmaceutical and biotechnology ecosystem. According to the Government of India, the country is the world's largest vaccine producer and supplies approximately 60% of global vaccines. India also supplies vaccines to international immunization programs and accounts for approximately 55%–60% of UNICEF's vaccine procurement volumes.

The country's pharmaceutical, vaccine, biotechnology, generic drug, and contract research industries, combined with increasing emphasis on indigenous drug development, biologics, biosimilars, and advanced R&D, are creating favorable conditions for broader adoption of drug discovery informatics platforms.

Product and Mode Analysis

Based on product, the drug discovery informatics market is segmented into discovery informatics and development informatics. Discovery informatics supports activities associated with identifying and evaluating potential drug candidates, while development informatics supports data management and computational requirements as promising candidates progress through the development process.

Based on mode, the market is categorized into in-house informatics and outsourced informatics. Pharmaceutical and biotechnology companies may maintain internal informatics capabilities, while outsourcing enables organizations to access specialized technologies, expertise, and computational infrastructure through external providers.

Function and End-user Analysis

By function, the market is segmented into sequencing and target data analysis, docking, lead generation informatics, identification and validation informatics, molecular modeling, and others.

These functions support different stages of computational drug discovery, from analyzing biological information and identifying therapeutic targets to generating and evaluating potential leads and modeling molecular interactions.

By end-user, the market is classified into pharmaceutical and biotechnology companies, contract research organizations, and others. Pharmaceutical and biotechnology companies represent a major user base due to their extensive R&D activities, while CROs increasingly utilize informatics technologies to support outsourced drug discovery and development programs.

Competitive Landscape

Prominent companies operating in the global drug discovery informatics market are investing substantially in pharmaceutical informatics and computational drug discovery technologies. Companies are advancing conventional drug-testing approaches and developing data-driven platforms designed to address challenges faced by pharmaceutical researchers and healthcare organizations.

Key companies include Charles River Laboratories International, Inc., Thermo Fisher Scientific, Inc., Revvity, Inc., Dotmatics, Dassault Systèmes SE / BIOVIA, Insilico Medicine, Inc., Collaborative Drug Discovery, Inc., Schrödinger, Inc., Curia Global, Inc., and Certara, Inc.

Market participants are focusing on AI-powered drug discovery, computational modeling, scientific data management, predictive analytics, and integrated research platforms. Strategic collaborations are also becoming important as pharmaceutical companies seek access to specialized AI and informatics capabilities.

These companies are profiled based on company overview, business strategies, product portfolios, financial overview, business segments, sales footprint, and recent developments.

Key Developments in the Drug Discovery Informatics Industry

In September 2026, Iktos and Pierre Fabre Laboratories entered into an integrated drug discovery collaboration focused on identifying and developing novel small-molecule oncology candidates. Under the agreement, Iktos is expected to deploy its AI-driven generative molecular design platform, while Pierre Fabre contributes oncology research, biology, medicinal expertise, and preclinical-development capabilities to evaluate and advance selected candidates.

In July 2026, Insilico Medicine initiated a Phase III clinical trial of rentosertib, its AI-enabled TNIK inhibitor for idiopathic pulmonary fibrosis. The candidate originated from Insilico's Pharma.AI platform, with both the therapeutic target and molecule developed using AI-supported discovery approaches. Its progression into Phase III represents a significant clinical milestone for AI-enabled drug discovery.

Future Outlook for the Drug Discovery Informatics Market

The global drug discovery informatics market is projected to expand from US$ 4.8 Bn in 2025 to US$ 15.1 Bn by 2036, representing a CAGR of 10.8% from 2026 to 2036.

Increasing pharmaceutical R&D expenditure is expected to remain a fundamental market driver as companies seek to improve research productivity and manage increasingly complex scientific datasets. At the same time, the adoption of AI, machine learning, predictive analytics, molecular modeling, and virtual screening is transforming the way pharmaceutical and biotechnology companies identify and evaluate potential drug candidates.

The growing volume of genomic, proteomic, chemical, phenotypic, and clinical data is increasing the importance of integrated informatics infrastructure. Platforms capable of organizing and analyzing these datasets can support target identification, candidate selection, molecular prediction, and other early-stage discovery activities.

North America is expected to maintain its strong position due to its mature pharmaceutical ecosystem and substantial R&D investments, while Asia Pacific is positioned for rapid expansion as pharmaceutical outsourcing, biotechnology research, AI adoption, and domestic drug discovery capabilities increase.

The convergence of artificial intelligence, advanced data science, scientific databases, and computational drug discovery is expected to remain a defining factor in the evolution of the drug discovery informatics market through 2036.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=33713<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Bone Wax Market

Internet of Medical Things Market

AI-Powered Healthcare Market

Value-Based Healthcare Solutions Market

Digital Twin in Healthcare Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com